

US-China Biopharm Congress 2014

SAPA-GP 12th Annual Conference

大费城美中医药协会2014年年会

Advancing Global Human Health through Collaborative R&D

Villanova University, Connelly Conference Center
800 Lancaster Avenue, Villanova, PA 19085
June 20-21, 2014



SAPA-GP

Sino-American Pharmaceutical
Professionals Association
- Greater Philadelphia

Co-Organizers



Tianjin Binhai Anti-Cancer Drug
Development Industry Union



American Association of
Pharmaceutical Scientists



ACS
Chemistry for Life®

Greetings from Conference Co-Chairs

Dear SAPA-GP Members and Friends:

On behalf of the Sino-American Pharmaceutical Professionals Association-Greater Philadelphia Area (SAPA-GP), we would like to welcome you all to 2014 SAPA-GP Annual Conference at Villanova University Connelly Conference Center, PA on June 20 and 21, 2014.

Global collaboration is one of the key elements in advancing human health and bringing the medicine to patients. SAPA-GP Annual Conference Organizing Committee has built an excellent program around the theme “Advance Global Human Health through Collaborative R&D”. This exciting one and a half day conference will focus on 1) cutting-edge science to address unmet medical needs, 2) global collaboration to enhance R&D efficiency, 3) market access for commercial success, and 4) government and industry partnership to bring new medicine to patients. Prominent policymakers, senior executives, and internationally renowned experts from the US and China will share their ideas and insights on these critical topics. We know you will enjoy the conference!

We are also meeting to celebrate another very successful year for the organization. To fulfill the SAPA-GP mission, this year we have focused on 4 key areas 1) Increasing SAPA-GP global influence in pharmaceutical/biotech fields, 2) Serving SAPA-GP members and the community better, 3) Building a strong team, and 4) further strengthening SAPA-GP finances.

Firstly, SAPA-GP has played an increasingly important role in facilitating the cooperation in pharmaceutical/biotech fields between the US and China. This year SAPA-GP has organized/co-organized several major pharmaceutical/biotech conferences in the China and US (See 2013-2014 SAPA-GP Accomplishments) and has received excellent feedback from participants. Among many accomplishments related to SAPA-GP's global influence, this year's establishment of a liaison office and long-term collaboration agreement with China Pharmaceutical Technology Transfer Center (CPTTC) in Beijing, China is a remarkable milestone. The launch of the Beijing Liaison Office has created a new platform for SAPA-GP to build international outreach in the pharmaceutical community and to lead and to promote further collaboration on a worldwide basis.

SAPA-GP's growing stature within the professional community is recognized in many fronts. This year “China Pharmaceutical Technology Economics and Management”, a prominent professional magazine in China, has created a dedicated “SAPA-GP Column” to invite SAPA-GP leaders and members to share their vision for the pharmaceutical & biotech industry and/or their professional insights on the cutting edge science and technology. “SAPA-GP Column” has become another effective tool for SAPA-GP to better facilitate the advancement of pharmaceutical science/technology in China and to ultimately bring solutions/strategies to meet unmet medical needs of patients in the US and in China.

Secondly, we view our members as our most valuable asset. Serving our members better, building a strong, efficient and effective team, and giving back to the community are among our top priorities in 2013-2014. This year we have organized seven webinars that were designed to

help our members to embrace many challenges in a changing pharmaceutical/biotech industry. True to our member-serving tradition, we successfully organized 2014 Annual Career Development Workshop which was well attended and highly praised by the attendees. Additionally we have organized several social/networking events including SAPA-GP Working Group Celebration/Appreciation, SAPA-GP All Members/Friends Picnic, and SAPA-GP Chinese New Year Celebration for team building and networking. Besides, talent development and identifying SAPA-GP future leaders are two very important strategic priorities we have focused on and put in great deal of efforts throughout the past year. We effectively used all SAPA-GP activities and events including Annual Conference, Career Development Workshop, webinars, tasks and special projects to further build unique SAPA-GP Team Culture and Core Value, and equally importantly, to develop our members and leaders in our organization. We are very proud to see great progress in this area.

Finally, building a strong financial foundation, another top priority in 2013-2014, is the key to our sustained growth and success in the future. Under the strong leadership of SAPA-GP Business Service Committee and Senior Leadership Team, SAPA-GP members have been working diligently on fund-raising. This year, our donors have been very generous and we set a new record. Given the very challenging and changing environment in pharmaceutical/biotech industry, we are extremely appreciative of our generous donors and the SAPA-GP members that invest the time to contact them. Their donations help us run excellent conferences such as this.

SAPA-GP has enjoyed significant growth and success, thanks to the enthusiastic participation and contribution from all SAPA-GP members. We would like to take this opportunity to thank SAPA-GP Senior Leadership Team, all members, volunteers, and friends for their hard work, impressive levels of dedication, and fantastic support! It has been a challenging, but exciting and rewarding year for SAPA-GP and we are glad to be part of this with all of you together!



Weiguo Dai, PhD
SAPA-GP President
Conference Co-Chair



Xi-Yong (Sean) Fu, PhD, MBA
SAPA-GP President-Elect
Conference Co-Chair



**US-China BioPharm Congress
Philadelphia 2014
SAPA-GP**

12th Annual Conference

Organizing Committee

Co-Chairs:

Weiguo Dai and Xi-Yong (Sean) Fu

Members:

Kelvin Bai	Yin Liang	Xizhuo Wang
Bei Chen	Zak Huang	Di Wu
David Cragin	Aston Liu	Hao Wu
Zhibiao Fu	Allen Luo	Shuang (Steve) Wu
Lili Guo	Yangsi Ou	Feiyu Xiong
Laura Hong	Joe Powers	Jing Yang
Tianjing Hu	Fang Shen	Mike Yu
Weihong Hsing	Bin Shi	Jennifer Yuan
Tao Jiang	Weifeng Tang	Aming Zhang
Mabel Ju	Chin Kim Ty	Sean Zhang
Jiangfan Li	Hui Wang	Yue-Mei Zhang
Yutai Li	Kun Wang	Shuxia Zhou
Xue Liang		

Art Design:

Lili Guo

Brochure Editing:

Fang Shen, Tianjing Hu, Xizhuo Wang

SAPA-GP Advisory Committee

Chair: Sean Zhang (President 2012-2013)

Laura Hong (President 2011-2012)	Jian Li (President 2006-2007)
Jingsong Wang (President 2010-2011)	Li Shi (President 2005-2006)
Tsang-Bin Tzeng (President 2009-2010)	Hancheng Zhang (President 2004-2005)
Li Yan (President 2008-2009)	Bo Liang (President 2003-2004)
Zhongda Zhang (President 2007-2008)	De-Min Zhu (Treasurer)

SAPA-GP Scientific Advisory Committee

RuiPing Dong, MD, PhD	Former SVP, Head of Emerging Market R&D, Merck & Co, Inc.
Evan Loh, MD	Former SVP, Pfizer Inc.
David Shen, PhD	Vice President, NGM Biopharmaceuticals, Inc.
Steven Yang, PhD	EVP and Chief Operating Officer, WuXi App Tec
Zhenping Zhu, MD, PhD	Executive VP, Kadmon, President and CEO, Kadmon China

SAPA-QP's Mission

To serve its membership, the pharmaceutical sciences, the biomedical and biotechnological community, the health professions, and the interest of the public health by:

- Promoting all aspects of the pharmaceutical and biopharmaceutical sciences, including both academic as well as industrial interests and providing for recognition of individual achievement;
- Fostering education, career growth and the personal development of its members;
- Providing a forum for open interchange and dissemination of scientific knowledge;
- Bridging and developing the relationship in the pharmaceutical area between the US and China.

SAPA-QP EC Committee

Members:

Kelvin Bai	Mabel Ju	Hui Wang
Bei Chen	Jiangfan Li	Kun Wang
David Cragin	Yutai Li	Xizhuo Wang
Weiguo Dai	Xue Liang	Di Wu
Xi-Yong (Sean) Fu	Yin Liang	Hao Wu
Zhibiao Fu	Aston Liu	Feiyu Xiong
Lili Guo	Allen Luo	Jing Yang
Laura Hong	Yangsi Ou	Mike Yu
Tianjing Hu	Joe Powers	Jennifer Yuan
Zak Huang	Fang Shen	Aming Zhang
Weihong Hsing	Bin Shi	Sean Zhang
Tao Jiang	Weifeng Tang	Shuxia Zhou

SAPA-GP Accomplishments (2013-2014)

Key Milestone

- Launched Liaison Office of SAPA-GP at China Pharmaceutical Technology Transfer Center (CPTTC), Beijing, China. May 2014.

Scientific Meetings

- SAPA-GP 12th Annual Conference on "Advancing Global Human Health through Collaborative R&D". June 20-21, 2014.
- Shanghai Bio-Forum, Shanghai, China. May 2014. Co-organizer with two session Chairs and 5 presentations.
- 2014 Asian Regional Drug Development Summit, Shanghai, China. February 2014. Co-organizer with one presentation.
- SAPA-GP Career Workshop, "Navigating towards Career Success in a Changing Biopharma Environment." November 2013.
- The 11th China International Pharmaceutical Technology Innovation and Industrialization Summit, Shanghai, China. October 2013. Co-organizer with a session Chair and 5 presentations.
- The 17th Beijing International Healthcare Industry Forum, Beijing, China. October 2013. Co-organizer with one session Chair and one presentation.

Partnership in Collaboration on Scientific Meetings

- Inaugural PEGS China. Protein & Antibody Engineering and Development Summit, Shanghai, China. April 1-3, 2014.
- 2013 PharmAsia Summit, Shanghai, China. October 2013. 2013 FDLI International Conference, Beijing, China, October 2013.

Webinars

- Analytical development and its role in the development and lifecycle management of pharmaceutical products. Xiande (Andy) Wang, PhD, Technical Owner/Principal Scientist, Janssen Pharmaceuticals Inc. May 21, 2014.
- Hatch-Waxman Litigation: The War Between Brand And Generic Goes To Court. *Hui Liu, Ph.D., J.D., Morrison & Foerster LLP. April 28, 2014.*
- How to Avoid Trade Secret Problems When You Change Jobs or When You Hire a New Employee. *Frederick A. Tecce, Partner at Panitch Schwarze Belisario & Nadel LLP, Former Assistant U.S. Attorney in the Criminal Division. February 27, 2014.*
- The Role of Medicinal Chemistry in Drug Discovery. *Dr. Yue-Mei Zhang, Sr. Principal Scientist, Johnson & Johnson. December 2, 2013.*
- Introduction to Drug Discovery Biology: Target identification, Validation and Screening Assays. *Dr. Jing Yang, Sr. Principal Scientist, Bristol-Myers Squibb Company. October 31, 2013.*
- The Glaxo-China Bribery Scandal and Beyond: The Enforcement of Anti-Bribery and Corruption Law Goes Global. *Hui Liu, Ph.D., J.D., Morrison & Foerster LLP. September 27, 2013.*
- Business Perspective of Biopharmaceutical Sciences. *Sean (Xiyong) Fu, PhD., MBA, Director of Financial Planning & Analysis, Merck & Co. June 10, 2013.*

Exchange forums with China Biopharma

- Shanghai Zerun Biotechnology /Walvax, April 27, 2014.
- Sichuan Kelun Pharma, December 10-12, 2013.
- Guangxi China Center for Disease Control and Prevention Delegate visit/meeting, December 9, 2013.
- Shandong Fangming Pharmaceutical Group Co., Ltd., November 7, 2013.

Publications

- SAPA-GP News Magazine, April 2014, Volume 11, Issue 2.
- A special column by SAPA-GP in "China Pharmaceutical Technology Economics and Management", a professional magazine published by CPTTC. 2014.

IT Accomplishment

- Launched all-new SAPA-GP website www.sapa-gp.org with greatly enhanced capability and user interface. 2014.
- Launched SAPA-GP Official Weibo/微博 campaign, posted over 100 entries and attracted over 360 followers. 2014.

Member Activities

- SAPA-GP Spring Picnic, May 2014.
- SAPA-GP Chinese New Year celebration, December 2013.
- SAPA-GP Working Group Celebration/Appreciation, August 2013.



Conference Agenda

Friday, June 20, 2014

1:00 – 1:30 PM

Check-in and Networking

1:30 PM – 1:40 PM

Opening Remarks

Weiguo Dai, PhD

President, SAPA-GP; Scientific Director/Janssen Fellow, Johnson and Johnson

1:40 – 2:00 PM

SAPA-GP Presidential Candidates: Introduction and Q&A

Moderator:

Xi-Yong (Sean) Fu, PhD, MBA

President-Elect, SAPA-GP; Director, Financial Services and Operations, Merck & Co., Inc.

Session I: Cutting-Edge Science to Address Unmet Medical Needs

2:00 – 4:40 PM

Moderators:

Aston Liu, PhD

Senior Manager, Biopharm R&D, GlaxoSmithKline

Jing Yang, PhD

Senior Principal Scientist, Discovery Biology, Bristol-Myers Squibb

2:00 – 2:35 PM

Keynote Address

Exploring New Models in Healthcare Innovation

Robert Urban, PhD

Head of Corporate Innovation Center (Boston), Johnson and Johnson

2:35 – 3:10 PM

Keynote Address

Trends in Monoclonal Antibody Therapeutics: from the Promising Innovation in Immune Oncology to the Expectations around Biosimilars

Richard Murray, PhD

Senior Vice President, Biologics & Vaccines Research, Merck Research Laboratories

3:10 – 3:25 PM

Coffee Break, Networking, Exhibit Booth Viewing
(Sponsored by GenScript)



3:25 – 3:45 PM

Research Collaborations as a Critical Component to Drug Discovery

Albert Seymour, PhD

Head of Research and Non-Clinical Development, Shire

3:45 – 4:05 PM

Discovery and Validation of Disease Biomarkers: An Opportunity for Academic / Industry Collaboration

Ian A. Blair, PhD

A.N. Richards Professor of Pharmacology; Vice-Chair, Department of Pharmacology; Director, Center for Cancer Pharmacology; Director, Penn Superfund Research Center, Perelman School of Medicine, University of Pennsylvania

4:05 – 4:40 PM

Keynote Address

Graduate Education in the Pharmaceutical Sciences: What is the Path Forward?

Marilyn E. Morris, PhD

President, American Association of Pharmaceutical Scientists (AAPS); Professor, University at Buffalo, The State University of New York

Panel Discussion: Emerging Trends in Drug Discovery

4:40 - 5:25 PM

Moderators:

Tianjing (TJ) Hu, PhD

Senior Scientific Liaison, moksha8 Pharmaceuticals, Inc.

Bin Shi, PhD

Research Fellow, Oncology, Merck & Co., Inc.

Panelists:

Kim Folander, MS

Executive Director, Business Development and Licensing, Merck Research Laboratories

Linden Gledhill, PhD

Senior Director, Biopharm Medicines and Process Delivery (BioMPD), Biopharm R&D, GlaxoSmithKline

Linus Lin, PhD

Vice President, Operation and Chemistry, Global Head of Chemistry Technology and Services, WuXi AppTec

Faming Zhang, PhD, MBA

Founder & CEO, Waterstone Pharmaceuticals, Inc.

Cocktail Reception

大费城美中医药协会欢迎酒会

(Complimentary to All Registered Attendees and Speakers)

5:25 – 6:00 PM

Sponsored by Kelun Pharmaceutical Co., Ltd.



Opening Night Gala of Wuhan Biolake

6:00 – 10:00 PM

武汉光谷之夜



武|汉|生|物|技|术|研|究|院
WUHAN INSTITUTE OF BIOTECHNOLOGY

Biolake
光谷生物城

Masters of Ceremony:

David Cragin, PhD

Associate Director, Chemical Notification and Registration, Merck & Co., Inc.

Mabel Ju, MS, MBA

Senior Financial Analyst, Financial Planning & Analysis, Merck & Co., Inc.

6:00 – 6:10 PM

Special Remarks

Patrick Toomey

US Senator for Pennsylvania

6:10 – 6:20 PM

Special Remarks

Patrick Meehan

Congressman, representing Pennsylvania's 7th Congressional District

6:20 – 6:30 PM

Special Remarks

Dongbai Ye (叶冬柏)

Science and Technology Counselor, Consulate General of P. R. China in New York

(中国驻纽约总领事馆科技参赞)

6:30 – 7:00 PM

Keynote Speech: Biolake – from Strategic Vision to Global Arena

Deping Qian

Executive Vice Dean, Wuhan Institute of Biotechnology, Wuhan National Bioindustry Base (Biolake)

7:00 – 7:15 PM

SAPA-GP Year in Review

Weiguo Dai, PhD

President, SAPA-GP; Scientific Director/Janssen Fellow, Johnson and Johnson

7:15 – 7:35 PM

Awards Ceremony

Weiguo Dai, PhD

7:35 – 10:00 PM

Live Music Performance (Jack Zhang, Clarinet; ArCoNet String Trio)

Dinner and Networking



Jack Zhang, Clarinet

Rising senior at Wissahickon High School. Currently studying clarinet under Dragan Chupinsky Petrovic, former Principal Clarinetist of the Belgrade Philharmonic Orchestra. Winner of Year 2014 ALL-American Young Artist Competition organized by the US Army Field Band and the National Association for Music Education (NAfME).

Repertoire: Carl Maria von Weber – Concertino for Clarinet, Op. 26
Piano accompaniment: Gabriel Rebolla



ArCoNet String Trio is comprised of faculty, alumni and assistants from ArCoNet, the Arts & Community Network, a non-profit organization dedicated to promoting the practice, education and participation of music and arts as a vehicle of social action and community development.



Daniela Diaz, Violin

ArCoNet College preparation program alumna, summer intern and assistant. Violin performance Student at Michigan State University. Former member of the Venezuelan Simon Bolivar orchestra.



Adriana Linares, Viola

ArCoNet President, Director and Founder. Violist of the Dali String Quartet. Recording artist, pedagogue, lecturer, and string coach.



Andres Sanchez, Cello

ArCoNet College preparation program alumnus, summer intern and assistant. Currently studying cello performance at the Curtis Institute of Music in Philadelphia. Member of Curtis on tour.

Repertoire

Selections from Mozart and Beethoven string trios

Selections from tango, jazz, Spanish music, classical and romantic styles

Saturday, June 21, 2014

8:00 – 8:45 AM

Check-in and Networking

8:45 – 8:50 AM

Welcome Remarks

Weiguo Dai, PhD

President, SAPA-GP; Scientific Director/Janssen Fellow, Johnson and Johnson

Session II: Global Collaboration to Enhance R&D Efficiency

8:50 – 10:55 AM

Moderators:

Yin Liang, PhD

Scientific Director/Janssen Fellow, Johnson and Johnson

Allen Luo, MS

Co-Founder at Niracle; Senior Director, Technology & Business Development at AstaTech Inc.

8:50 – 9:25 AM

Keynote Address

Some “Simple Solutions” to Improve R&D Efficiency

Joseph Tarnowski, PhD

Senior Vice President of Chemistry, Manufacturing and Controls (CMC), Biopharm R&D, GlaxoSmithKline

9:25 – 9:45 AM

Diabetes Drug Discovery: Strategies and Challenges

Keith Demarest, PhD

Vice President, Head of Cardiovascular & Metabolism Research, Johnson & Johnson

9:45 – 10:05 AM

Inspiring Business and Collaboration Opportunities with Innovative Nano Technologies

De-Min Zhu, PhD

Chief Executive Officer, Cureport, Inc.

10:05 – 10:40 AM

Keynote Address

Global Collaboration from Startup Company’s Perspective

Faming Zhang, PhD, MBA

Founder & CEO, Waterstone Pharmaceuticals, Inc.

10:40 – 10:55 AM

Coffee Break, Networking, Exhibit Booth Viewing

(Sponsored by Sundia)



Session III: Market Access for Commercial Success

10:55 AM – 12:10 PM

Moderators:

Xi-Yong (Sean) Fu, PhD, MBA

President-Elect, SAPA-GP; Director, Financial Services and Operations, Merck & Co., Inc.

Fang Shen, PhD

Principal Scientist, Immunology Discovery, Johnson and Johnson

10:55 - 11:30 AM

Keynote Address

Better Serve Customers & Create Value through Services: the Pharma Case

Guy Eiferman, MEng, MBA

Senior Vice President, Strategic Planning and Managing Director, Healthcare Services and Solutions, Merck & Co., Inc.

11:30 – 11:50 AM

Chinese Pharmaceutical and Biotech Industry - Becoming Innovative Global Players, CRO Perspectives

Honggang Bi, PhD

Corporate Vice President, General Manager, Covance China

11:50 AM – 12:10 PM

Genome Writing and Editing- a New Phase of Post-Genomics Era

Jeffrey Hung, PhD, MBA

Vice President, Service Marketing, GenScript

Lunch

(Complimentary to All Registered Attendees and Speakers)

12:10 – 1:30 PM

Sponsored by Kelun Pharmaceutical Co., Ltd.



Session IV: Government, Academia and Industry Partnerships to Bring Medicines to Patients

1:30 – 3:20 PM

Moderators:

Di Wu, PhD

Director, Division of Clinical Pharmacology & Therapeutics, Children's Hospital of Philadelphia

Sean Zhang, MD, FCP

Immediate Past President, SAPA-GP; Senior Medical Director, Biopharm Translational Medicine, GlaxoSmithKline

1:30 – 2:05 PM

Keynote Address

Partners for Progress and Prosperity: A Personal & Professional Journey

Marinda Li Wu, PhD

2013 President, American Chemical Society (ACS)

2:05 – 2:25 PM

Effective Global R&D Collaboration: Kelun Model and Strategy

Lichun Wang, MS / Wenjia Li, MS

Representatives, Sichuan Kelun Pharmaceutical Co., Ltd.

2:25 – 2:45 PM

Discovery on Target: Integrated Proteomics Solutions for Diagnostics and Therapeutics.

Zhongyi Cheng, PhD

Co-Founder and Chief Executive Officer, PTM Biolabs

2:45 – 3:05 PM

The Cultural Issues in Partnering in China

John Bennett, MD

President and Chief Executive Officer, Devon International Group

3:05 – 3:20 PM

Coffee Break, Networking, Exhibit Booth Viewing

(Sponsored by Covance)



Panel Discussion: Collaboration from a Business Perspective

3:20 - 4:05 PM

Moderators:

John Bennett, MD

President and Chief Executive Officer, Devon International Group

Kun Wang, PhD

Research Scientist, University of Medicine and Dentistry of New Jersey

Panelists:

Charles Huang, PhD

Vice President, Business Development, Sundia

Feng (Frank) Li, PhD

President and Co-Founder, Alliance Pharma, Inc.

Wayne Li, PhD

General Manager, Kunming Biomed International (KBI); General Manager, Harmonia (Tianjin) Biotechnology; Investment Director, Morningside Technologies

David Niles

Executive Director, Montgomery County Development Corporation

Dongmei Wang, PhD

Senior Vice President and General Manager, CMC Services Division, Frontage Laboratories Inc.

4:05 – 4:10 PM

Closing Remarks

Xi-Yong (Sean) Fu, PhD, MBA

President-Elect, SAPA-GP; Director, Financial Services and Operations, Merck & Co., Inc.

4:10 – 4:20 PM

Raffle Drawing

Notes

Speaker Bios

Listed in Alphabetical Order of Last Name



John Bennett, MD

President and Chief Executive Officer, Devon International Group

For the last 35 years, Dr. John A. Bennett, MD, has been one of the most recognized entrepreneurs and businessmen in the Philadelphia area. A local and national leader in the healthcare and technology industries, Dr. Bennett is currently the President and CEO of the Devon International Group.

Dr. Bennett joined Delaware County Memorial Hospital as an emergency room physician in 1978. Three years later, he was elected to the hospital's Medical Executive Committee and made Director of Emergency Services. In June of 1984, he was elected president of the Medical Executive Committee.

In 1984, Dr. Bennett founded ATI Centers, Inc., which consisted of 13 outpatient diagnostic imaging and physical therapy centers located throughout Pennsylvania and New Jersey. Fueled by immediate interest in the company, Dr. Bennett and a handful of employees set out to build a preferred provider organization (PPO) with services to encompass all provider specialties – and succeeded. The company was renamed Devon Health Services, Inc. in 1995 and is now the largest privately owned PPO in the Northeast United States.

The success of Devon Health has given Dr. Bennett the opportunity to expand into the different sectors of what now comprise the DIG group of companies. Consilium is an out-of-network healthcare claims company that uses expert negotiation and a proprietary, patent-pending business intelligence software tool to generate substantial savings for customers. Devon IT is a technology company and the world's third largest provider of software that manages thin client desktop devices. Devon Medical Products is a global designer and manufacturer of medical devices used to treat wounds, complications from diabetes, and other health complications. And DIG also has various other entities operating in various verticals worldwide.

Dr. Bennett preaches the “Blue Ocean Strategy” – developing new markets rather than competing in bloody, competitive ones – and “The World is Flat” – conducting business on an international scale. Today DIG has over 500 employees operating in 22 countries.

Dr. Bennett is a true entrepreneur who identifies unique products and services that enhance global business. His work takes him throughout the world, where his international relationships and business partnerships help drive revenue in domestic markets.



Honggang Bi, PhD

Corporate Vice President, General Manager, Covance China

Dr. Honggang Bi is the Corporate Vice President for Covance Inc., and General Manager for Covance China. He is responsible for leading all Covance business and service activities in China including preclinical and clinical development, as well as central laboratory services, and representing Covance in front of various Chinese regulatory and government agencies.

Since joining Covance in 2007, Dr. Bi has led the rapid growth for Covance China, expanded service offering for local, regional and global clients.

Since the early 90's, Dr. Bi has advanced his career with increasing management responsibilities at various pharmaceutical companies such as SmithKline Beecham, Parke-Davis and Pfizer. Dr. Bi's scientific achievement can be evidenced by more than 30 research publications and various presentations at scientific conferences. Prior to joining Covance, Dr. Bi was the CEO of Frontage Laboratories and led significant growth for the company both in US and China.

Dr. Bi received his Bachelor of Pharmacy from Zhejiang University and his graduate training at the Chinese Academy of Medical Sciences. He received his PhD in chemistry and drug metabolism from McGill University in Montreal, Canada.



Ian A. Blair, PhD

A.N. Richards Professor of Pharmacology; Vice-Chair, Department of Pharmacology; Director, Center for Cancer Pharmacology; Director, Penn Superfund Research Center, Perelman School of Medicine, University of Pennsylvania

Dr. Blair received his PhD in Organic Chemistry in 1971 from Imperial College of Science and Technology, London, under the mentorship of the 1969 Nobel Laureate, Sir Derek H.R. Barton. He was appointed as the A.N. Richards Professor of Pharmacology at University of Pennsylvania in 1997 and Director of a new Center for Cancer Pharmacology. In 2002, Dr. Blair was appointed as Vice-Chair of the Department of Pharmacology and in 2003 Director of the Proteomics and Systems Biology Facility. He is an expert in the use of mass spectrometric methods for the structural elucidation and quantification of endogenous biomolecules. Dr. Blair's current research is involved with the development of biomarkers in order to establish genetic/phenotype correlations and to assess the interaction between genes and exposure to environmental chemicals. He is particularly interested in the regulation of cellular oxidative stress and how this underpins mechanisms involved in carcinogenesis and cardiovascular disease. Dr. Blair discovered electron capture atmospheric pressure chemical ionization, a technique that makes it possible to conduct high sensitivity quantitative analyses of chiral biomolecules. He is a Fellow of the American Association for the Advancement of Science and the American Association of Pharmaceutical Scientists. He received the 2011 Eastern Analytical Award for Outstanding Achievements in Mass Spectrometry. Dr. Blair is on the editorial boards of the Molecular and Cellular Proteomics, Journal of Lipid Research, and Chemical Research in Toxicology. He has published over 320-refereed manuscripts, which have been cited over 13,000 times, and he has an h-index of 58.



Zhongyi Cheng, PhD

Co-Founder and Chief Executive Officer, PTM Biolabs

Dr. Zhongyi Cheng (Jack) is the Chief Executive Officer and co-founder of PTM Biolabs, Inc. Dr. Cheng has his expertise in protein post translational modifications (PTMs), epigenetics, and proteomics. In the past five years, Dr. Cheng has co-authored over 10 peer reviewed publications in the field of PTM proteomics for biomarker discovery and drug target screening. Dr. Cheng holds a PhD in Molecular and Cell Biology from the University of Science and Technology of China. He received his postdoctoral training at the University of Texas Southwestern Medical Center at Dallas and University

of Chicago. Dr. Cheng co-founded PTM Biolabs in 2010 and has since led the organization to become the leading developer for high quality antibodies against specific PTM pathways and histone marks. He has also co-developed high sensitivity PTM proteomic technology and applied it to preclinical pharmaceutical research and development. This integrated technology has profoundly advanced drug discovery process, especially for candidates targeting epigenetic mechanisms.



Keith Demarest, PhD

Vice President, Head of Cardiovascular & Metabolism Research, Johnson & Johnson

Education: B.S. Biology, Wheeling Jesuit University, Wheeling WV; PhD Pharmacology, West Virginia University, Morgantown WV; NIH Postdoctoral fellowship at Michigan State University, East Lansing MI.

After postdoctoral training in the Department of Pharmacology in the laboratory of Kenneth E. Moore in Neuropharmacology and Neuroendocrinology, Dr. Demarest was awarded a Career Development Award from the Pharmaceutical Manufacturers Association and joined the Departments of Pharmacology and Physiology at Michigan State University School of Medicine. Dr. Demarest progressed to the level of Associate Professor before joining Johnson & Johnson in 1986 as a Principal Scientist within drug Discovery Research. He led the Endocrine & Metabolic Research Drug Discovery Team in Raritan, NJ. And was promoted through the ranks of the scientific ladder to Distinguished Research Fellow and delivered multiple compounds into development. In 2006 Dr. Demarest took the position of Metabolic Diseases CDTL within Early Development in Spring House. In 2009 he took on his current position as Head of Research within the Cardiovascular Metabolic Therapeutic Area leading a group of 64 scientists in Springhouse, PA with the primary focus of the discovery and development of novel therapeutics for diabetes and heart failure.



Guy Eiferman, MEng, MBA

Senior Vice President, Strategic Planning and Managing Director, Healthcare Services and Solutions, Merck & Co., Inc.

Guy has a Master in Operational Research & Engineering from Ecole Centrale de Paris and an MBA in International Trade from the Institut d'Etudes Politiques de Paris.

Guy joined Merck in France in 1987 after a few years as a management consultant and, after having served as IT Director until 1991, has since held positions of increasing responsibility in Marketing, Business Development and General Management both in Europe and in the US. After serving in Business Development-European Operations in the worldwide Headquarters in New Jersey in 1993, he relocated to France and was successively appointed in the Merck subsidiary in France, Director of Market Research and Strategic Planning, Director of Generics Division, launching one of the first line of genuine generics in France, and Director of Marketing Operations.

In September 1999, Guy came back to New Jersey where he was appointed Executive Director of the Atherosclerosis Franchise, leading the worldwide marketing strategies for ZOCOR™. Guy then became Vice President and General Manager of the Cholesterol Partnership between Merck and Schering-Plough for Europe/Middle East & Africa from its creation in December 2001, leading

the international launch of what is now a multi-billion Franchise with brands such as INEGY and EZETROL. He was then appointed to create and lead a new function within Merck, Alliance Management, in October 2004 with the mindset of interacting with our partners, licensors and other biotech and pharmaceutical companies as true customers. In July 2006, he was promoted to the role of General Manager of the Atherosclerosis & Cardiovascular Franchise with responsibility for the entire CV portfolio on a worldwide basis.

In January 2009, Guy was promoted to Senior Vice President and Managing Director for MSD in France. He successfully led this \$ 2 billion & three thousand employee organization through 4 years of turbulent times with profound restructuring and reorganization following the merger between Merck and Schering-Plough. In January 2013, Guy was promoted to lead MSD Mid-Europe Region, a 20-country region in Europe gathering mid-size markets from the Netherlands to Portugal and from Greece to all Eastern European markets. Since November 2013, Guy is the Managing Director of a new entity, wholly owned by Merck, named Healthcare Solutions & Services (HSS). HSS is aimed at developing and commercializing globally a portfolio of services and solutions to add value to all stakeholders in the healthcare environment.

Guy is married to Noelle and has three children.



Kim Folander, MS

Executive Director, Business Development and Licensing, Merck Research Laboratories

Kimberly Folander received her BS from Drew University and an MS in biochemistry from the University of Connecticut. She joined Merck's department of Pharmacology as a staff biologist in 1987. For the next 14 years her research focused on the molecular biology, structure, function, and pharmacology of ion channels.

Kim joined Business Development and Licensing in 2001. She has been responsible for licensing activities involving Merck's genetically engineered models, RNAi, lentivirus, adenovirus, and molecular profiling technologies, imaging and platforms utilizing DNA, RNA, and proteins. Kim was involved in Merck's acquisition and recent sale of Sirna Therapeutics and had responsibility for the review and licensing of RNAi technologies for all stages of siRNA optimization, delivery and therapeutic applications. Her current areas of responsibility include licensing and acquisitions in the areas of Enabling Technologies as well as experimental medicine, molecular biomarkers and companion diagnostics.



Linden Gledhill, PhD

Senior Director, Biopharm Medicines and Process Delivery (BioMPD), Biopharm R&D, GlaxoSmithKline

Linden Gledhill, PhD is Senior Director of Biopharm Medicines and Process Delivery (BioMPD) within Biopharm R&D at GlaxoSmithKline (GSK). He has spent over 20 years within the pharmaceutical industry focused primarily on the research, development, registration and commercialization of antibiotic and biopharmaceutical products.

Linden earned a BS degree in Biochemistry from the University of York, UK and a PhD degree in Biochemistry from the Pharmaceutical Sciences Dept, University of Nottingham, UK where he

continued his research as a post-doctoral fellow. Following his research he was hired as a scientist to develop and optimize large scale antibiotic manufacturing processes within SmithKline Beecham Pharmaceuticals (GSK). In 2001, Linden moved to the US to join the Biopharmaceutical development organization within GSK to focus on the development, registration and launch of novel antibodies, chemokines and fusion proteins. During the last 18 years he has developed an extensive knowledge of what is required to develop Biopharmaceuticals as leader of the Protein Separations and Characterization teams and Director of Quality Control. More recently, Linden has focused on the leadership of chemistry and manufacturing development matrix teams to develop cell lines, fermentation/purification processes, formulations, devices and analytical testing capability to enable manufacture of supplies for both clinical studies and commercial launch. His knowledge of technology transfer and manufacturing scale up, including validation for registration has enabled the delivery of biopharmaceuticals with significant value to patients.



Charles Huang, PhD

Vice President, Business Development, Sundia

Charles Huang joined Sundia in March 2008, a top Chinese CRO that provides fully-integrated drug discovery and development services to its worldwide clients. Charles is currently Vice President of Global Business Development, responsible for all international markets including US and Europe, and part of China domestic market.

Prior to Sundia, Charles served as president of Amnova, a pharmaceutical consultant firm in US. He worked for 15 years as medicinal chemist at Neurocrine Bioscience Inc (NBI), Johnson & Johnson and Amylin, on projects including CRO project management and new market BD for advanced clinic candidate.



Jeffrey Hung, PhD, MBA

Vice President, Service Marketing, GenScript

Jeffrey Hung, PhD, is the Vice President of GenScript, a leading biology research service company in the world. Jeff, an innovative leader in growing startup companies, is responsible for gene synthesis applications. Jeff was the chief marketing officer at ATCC before joining GenScript. Prior to that role, he served as the Senior Director of Marketing at SABiosciences, growing the company rapidly, and was instrumental for the acquisition of SABiosciences by QIAGEN. He has held management and R&D positions at Invitrogen, Harvard Bioscience and Exelixis. Jeff earned his PhD from Cornell University,

MBA from UC Berkeley, and BS from Peking University.



Feng (Frank) Li, PhD

President and Co-Founder, Alliance Pharma, Inc.

Dr. Li obtained his Ph.D. in Bioanalytical Chemistry jointly from Canadian Doping Control Centre and Concordia University. Subsequently he received post-doctoral training in Biomedical Mass Spectrometry Facility at Mayo Clinic. Dr. Li also has a BS in Pharmacy and a MS in Medicinal Chemistry.


Professionally, Dr. Li has held responsible roles in the area of drug discovery metabolism at MDS Pharma Services (a major CRO), in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GSK Pharmaceuticals and in the Drug Metabolism group at Cephalon. Dr. Li has extensive DMPK experience in both drug discovery and development. He is a recognized expert in the field of bioanalysis and DMPK. He has more than 15 years of working experience in CRO, pharmaceutical and biotech industries.



Wayne Li, PhD

General Manager, Kunming Biomed International; General Manager, Harmonia (Tianjin) Biotechnology; Investment Director, Morningside Technologies

Dr. Wenbao (Wayne) Li obtained his Master of Science Degree in 1986 from the Research Center of Eco-Environmental Sciences, Chinese Academy of Sciences and PhD in 1995 from Brigham Young University. He did his post-doctoral research at the Haskell Laboratory for Toxicology and Industrial Medicine at DuPont Company where he subsequently worked as a research scientist for about 5 years. Dr. Li has held director and manager level positions at Genelabs, Rigel and Covance Laboratories. He has more than 21 years of experience in biological and chemical sciences, of which over 15 years were dedicated to drug discovery and development. His expertise is in novel drug preclinical development. He has directly participated and supported drug discovery and development projects for licensing out. He has also successfully negotiated and closed deals with multinational pharmaceutical companies. In 2007, Dr. Li relocated back from US to China and joined Morningside Technologies (a private VC firm focusing on healthcare investment) as an investment project manager. Since 2009, he was assigned as the General Manager of Kunming Biomed International (KBI) and Harmonia (Tianjin) Biotechnology Company. Both KBI and Harmonia are invested by Morningside Technologies to provide preclinical services for healthcare industry, biopharmaceutical industry and research academies. Dr. Li has more than 30 papers published in leading scientific journals and more than 50 presentations on national and international conferences and symposiums.



Wenjia Li, MS

Project Evaluation Specialist / Deputy Minister of Pharmacology, Kelun Pharmaceutical Research Institute

Wenjia Li is Project Evaluation Specialist / Deputy Minister of Pharmacology of Kelun Pharmaceutical Research Institute, Kelun Pharmaceutical, a pharmaceutical company headquartered in Chengdu, Sichuan and listed at Shenzhen Stock Exchange (SZ002422). In this position, Wenjia focuses on evaluating projects provided by sponsors based on many aspects such as the patent state, technical issue and the registration problem to provide advice by evaluation report and final project evaluating presentation. In addition, she is getting started with building up the internal training department, preparing for research center size expansion, hosting and planning internal and external meeting, and conducting the daily management of Pharmacology Department.

Previously, Wenjia worked as Data Coordinator (Clinical Trial) in MSD data management center, one of the four in global range to provide the clinical data management supporting work of MSD, where she took part in every step of clinical trial and was responsible for the entire project after 6 months (the Data Project Lead).

Before joining MSD, Wenjia was a DMPK Scientist in BioDuro. She worked on analyzing the organic compound in low MW using LC/MS/MS, LC, and GC of all kinds of samples, especially method establishment and validation, followed by a QA Auditor in BioDuro with audit work of GLP lab (taking charge of the pre-clinical toxicology study data review), preparing data files in the founding of QAU and writing, revising and proof-reading of SOPs.




Linus Lin, PhD

VP, Operation and Chemistry, Global Head of Chemistry Technology and Services, WuXi AppTec

Dr. Linus Lin serves as the Vice President of Operation and Chemistry, Global Head of Chemistry Technology and Services at WuXi AppTec. Dr. Lin leads the Chemistry Service Unit, reporting to CEO Dr. Ge Li. He is responsible for strengthening WuXi's global leadership in chemistry technology and services with expanding capabilities.

Dr. Lin has over 20 years of experience in the field of organic and medicinal chemistry and in building high performance teams. Before joining WuXi AppTec, Dr. Lin was the Global Chemistry Operations Lead of Merck Research Laboratories. Prior to that, he was a Chemistry Collaboration Lead of Merck's External Discovery and Preclinical Sciences department, during which he helped Merck to build external capability and led drug discovery programs to augment company's product pipeline through partnerships with biotechnology companies, contract research organizations, and academic institutions. During his 14-year career at Merck, he and his team successfully delivered seven preclinical candidates, including one that completed PhIII study. Dr. Lin graduated from Peking University with a Bachelor's Degree in Chemistry at the age of 18. He then obtained his Master's degree and PhD degree in Organic Chemistry from Chinese Academy of Sciences and University of Wisconsin, respectively. Later, he studied at Harvard University as an NIH postdoctoral fellow under the direction of Nobel laureate Professor E.J. Corey.



Patrick Meehan

Congressman, representing Pennsylvania's 7th Congressional District

Congressman Patrick Meehan represents Pennsylvania's 7th District in the United States House of Representatives. In the 113th Congress, Meehan sits on the House Transportation and Infrastructure, Oversight and Government Reform, Homeland Security and Ethics committees. As a member of the Homeland Security Committee, he chairs the Subcommittee on Cybersecurity, Infrastructure Protection and Security Technologies.

Elected to Congress in 2010, Meehan has made economic growth in Southeastern Pennsylvania a top priority by supporting the revitalization of the area's refineries, the expansion of Philadelphia International Airport and the deepening of the Delaware River shipping channel – projects that mean jobs for the region. He's fighting to reform our broken tax code, championed funding for the National Institutes of Health and long been a strong supporter of Science, Technology, Engineering and Math (STEM) education.

A former United States Attorney for the Eastern District of Pennsylvania, Meehan is considered one of Congress' foremost experts on homeland security, terrorism and the prevention and prosecution of sex crimes. While a federal prosecutor, Meehan earned national acclaim for his

efforts to combat political corruption. Before his service in the Justice Department, Meehan served as the elected District Attorney of Delaware County, Pennsylvania. Today, Congressman Meehan lives with his wife Carolyn and their three sons in Drexel Hill, Pennsylvania.



Marilyn E. Morris, PhD

President, American Association of Pharmaceutical Scientists (AAPS);
Professor, University at Buffalo, The State University of New York

Dr. Morris is Professor and Vice-Chair in the Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, the State University of New York. She received her B.Sc. (Pharmacy) from the University of Manitoba, Canada, M.Sc. (Pharmacology) from the University of Ottawa, Canada, and PhD (Pharmaceutics) from the University at Buffalo. She was an Assistant Professor at Dalhousie University, Halifax, Nova Scotia, Canada and a Medical Research Council Fellow at the University of Toronto, Canada, before joining the University at Buffalo as an Assistant Professor. Her research focuses on the influence of drug transporters on drug pharmacokinetics and pharmacodynamics. She is the author of over 165 scientific papers. Her overall research contributions have been recognized through the presentation of the State University of New York Chancellor's award for excellence in research and creative activities, a Francis Dudley Meyer Award for Breast Cancer Research, Cancer Research and Prevention Foundation, and election as a Fellow of the American Association of Pharmaceutical Scientists and a Fellow of the American Association for the Advancement of Science. She was the recipient of the Faculty of Pharmacy University of Manitoba Distinguished Alumni 2013 award.

Dr. Morris has significantly contributed to graduate and postdoctoral education through her contributions as Associate Dean for Graduate and Postdoctoral Education in the Graduate School at the University at Buffalo (2006-2012). She has also been or currently is the major advisor to 28 PhD students, 11 MS, 6 BS/MS students, 10 postdoctoral scholars and many PharmD and undergraduate students.

Dr. Morris has provided significant contributions to the Pharmaceutical Sciences through her current role as elected President of the American Association of Pharmaceutical Sciences (AAPS). She has served since 2006 on the Food and Drug Administration (FDA) Advisory Committee in the Pharmaceutical Sciences and Clinical Pharmacology, as well as on National Institutes of Health and other grant review and advisory panels. Dr. Morris is an Associate Editor for the AAPS Journal and is on the Editorial Boards of the Journal of Pharmaceutical Science, Pharmaceutical Research, Biopharmaceutics and Drug Disposition and Molecular Pharmaceutics.



Richard Murray, PhD

Senior Vice President, Biologics & Vaccines Research, Merck Research Laboratories

Dr. Richard Murray joined Merck in February 2010 and is a member of the Merck Research Laboratories (MRL) leadership team. His responsibilities include oversight of the operational groups to discover and develop protein therapeutic modalities and vaccines, interfaced across the breadth of disease area strategies within Merck. In addition, he leads, with MMD and GHH colleagues, an external R & D and manufacturing collaboration with Samsung on Merck's portfolio of biosimilars.

Dr. Murray comes to Merck with two decades of experience in the Biologics arena from basic to translational research, overseeing clinical and commercial scale manufacturing, and supporting the supply chain of hospital based products. His experience spans from co-founding startup companies, leadership roles in mid-sized biotech companies, to his current role overseeing multiple sub-divisions of MRL.

Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. Dr. Murray was the prior EVP and CSO at PDL BioPharma. Previously, he was co-founder and VP of research at EOS Biotechnology. Prior to executive level roles, he spent over 10 years on the staff at DNAX Research Institute, which later became Schering Plough Biopharma, and now represents the main site for Merck's Biologics discovery efforts.



David Niles

Executive Director, Montgomery County Development Corporation

David A. Niles is the Executive Director of the Montgomery County Development Corporation (MCDC), which has been newly reconstituted as a partnership between the organization's private sector membership and Montgomery County's Commerce Department. David's role is to provide a single point of contact, with one phone call access to resources that have allowed county businesses to thrive in a very competitive region. David's organization has cooperated with the Redevelopment Authority to create competitive loans, Industrial Development Authority for cost effective training programs and with the Workforce Investment Board for creating a stronger and more effective county labor market.

Prior to his success with Economic Development initiatives in Montgomery County, Mr. Niles spent thirteen years in Commercial Real Estate. A significant amount of his energy was channeled into gaining a strong regional foothold in the life sciences, biotechnology and medical device sectors. David's collaborative abilities lead to an extremely effective partnership network among PA Department of Community and Economic Development (DCED, Pennsylvania Biotechnology Organization (PABio), BioStrategy Partners (BioSp) and Innovation x Ideas Network (i2n). These networks not only provided access to industry experts, but linking connections to service providers as well. Mr. Niles sits on the Board for both BioSP and i2n. Through BioStrategy Partners and i2n, Mr. Niles was able to consult for several University based Tech Transfer Offices (TTO). The initiatives of the TTO's, BioSP and i2n are the foundation of economic development in the purest form.

Today, in Mr. Niles capacity as Executive Director of MCDC, he has been instrumental in developing two new economic development initiatives in Montgomery County. A Municipal Services platform focused on providing consulting services to the 62 Communities within Montgomery County as well as The Manufacturing Alliance of Bucks County and Montgomery County. The Alliance is goal oriented and provides a 'one stop' shop/call for small (75 employees or less) manufacturing companies in Bucks and Montgomery Counties. The ultimate goal of creating economic value for businesses has been accomplished through the joint efforts of David's partners in Real Estate, township supervisors in the county communities and regional service providers supporting the manufacturing alliance.

Mr. Niles resides in Narberth with his wife Dana and his three children, Tyler, Lukas and Lily.



Deping Qian

Executive Vice Dean, Wuhan Institute of Biotechnology, Wuhan National Bioindustry Base (Biolake)

Mr. Qian was born in September 1965 in Hubei Tianmen. In 1991, he received his postgraduate degree from Shanghai Fudan University.

Mr. Qian served as Committee Organization Department Vice Minister of Wuhan East Lake Hi-tech Development Zone, director of Education, Culture and Public Health Bureau of East Lake Hi-tech Development Zone Administrative Committee. From December 2013, he started to serve as Executive Vice Dean of Wuhan Institute of Biotechnology.

During the work of the Committee Organization Department, Mr. Qian has put forward the idea of constructing China Optics Valley talent zone, which is supported by the municipal Party Committee Organization Department and Wuhan Personnel Bureau. He is actively involved in title evaluation, expert recommendation, and introduction of talents, creating a good environment in East Lake Hi-tech Development Zone for the recruitment and retention of talents.

As the director of Education Culture and Public Health Bureau, Mr. Qian has contributed creative thinking and efforts to the construction of school culture, teachers and personnel system reform, the balanced development of the school, the school performance management, and the implementation of quality education.

At present, Mr. Qian is in charge of the introduction and incubation of Wuhan Institute of Biotechnology innovation group, and the construction and management of the public equipment sharing center.



Albert Seymour, PhD

Head of Research and Non-Clinical Development, Shire

Albert is a human geneticist with more than 17 years of scientific and leadership experience in drug discovery and development. Albert joined Shire in April of 2011 and currently he is the Head of Research and Nonclinical Development (RNCD) at Shire. He is accountable for the strategy and operational direction of the RNCD Organization and has the responsibility for initiating new internal research programs, external partnerships to enrich the R&D portfolio, and transitioning programs from Research into Development. Prior to joining Shire, Albert held various leadership positions at Pfizer where his team applied human genetics and computational biology to discover and develop novel therapeutics targeting diabetes, inflammatory diseases, and cancer. Albert received his PhD in Human Genetics at the University of Pittsburgh, an MS in Molecular Genetics from Johns Hopkins University and his BA in Biology from the University of Delaware.



Joseph Tarnowski, PhD

Senior Vice President of Chemistry, Manufacturing and Controls (CMC) Biopharm R&D, GlaxoSmithKline

Joseph Tarnowski, PhD is Senior Vice President of Chemistry, Manufacturing and Controls (CMC) Biopharm R&D at GlaxoSmithKline (GSK). Before joining GSK in June, 2010, Joe was the Senior Vice President, Biologics Manufacturing

and Process Development in the Technical Operations division of Bristol-Myers Squibb Co. in New Brunswick, NJ. Joe was responsible for building the manufacturing capabilities needed to supply the company's biologic medicines to worldwide markets, including the construction of the company's new \$750 million large-scale multi-product bulk biologics manufacturing facility in Devens, Massachusetts, and the integration of Medarex, Inc. He has spent over 30 years in the pharmaceutical industry, focused primarily on the research, development, registration and commercialization of biopharmaceutical products made using recombinant DNA technology. He holds 13 patents and has several patent applications pending for biologic products.

Joe earned a BS degree in Chemistry from Southeast Missouri State University and a PhD degree in Biochemistry from the University of Tennessee Center for the Health Sciences. After receiving his PhD, Joe was awarded a post-doctoral fellowship in Molecular Biology at the prestigious Roche Institute of Molecular Biology, in Nutley, NJ.

Following his fellowship, Joe was hired to be a senior scientist to develop the large-scale protein purification processes necessary for the manufacture of Recombinant Protein Therapeutics. Interferon Sciences, Inc. recruited Dr. Tarnowski from Hoffman-LaRoche, and he later held senior positions at Scios (acquired by Johnson & Johnson), CellPro, Inc. (cell therapeutics company), and ImClone Systems Incorporated (acquired by Eli Lilly).

While at ImClone Systems, Joe grew the company's Branchburg, NJ Campus from one building on six acres to seven buildings on nearly 50 acres. After the completion of its second manufacturing plant in 2005, ImClone Systems was one the world's largest mammalian cell culture manufacturers.

Joe has held critical roles in the manufacturing, process development, registration, and launch of several FDA and internationally approved human therapeutic products, including Roferon[®] A, Alpheron N[®], Fiblast[®] Spray, CEPRATE[®] SC Stem Cell Concentration System, Natrecor[®], Erbitux[®] Orencia[®], Yervoy[®], Nulojix[®], and Eperzan[®]/Tanzeum[®]. He has a thorough understanding of the biologics drug registration process and has had extensive experience in developing the Chemistry, Manufacturing and Controls (CMC) sections for many Investigational New Drug and Biologics License Applications.



Patrick Toomey
US Senator for Pennsylvania

Senator Pat Toomey is a leader on economic, financial services, and budget issues. He is known as a champion of fiscal responsibility.

The Philadelphia Inquirer wrote that Senator Toomey has emerged as "a leading voice on money matters." He helped write and enact the bipartisan JOBS Act, which cuts regulatory burdens on small and medium-sized businesses making it easier for them to raise capital and create jobs.

The senator serves on the Finance; Banking; Budget; and Joint Economic committees. Sen. Toomey is the chairman of the Senate Steering Committee - the coalition of Republican senators that advocates for innovative, conservative policies.

Sen. Toomey previously was elected to the House of Representatives and fulfilled his three-term pledge. In addition to his public service, the senator also was the president of the Club for Growth,

owned and operated a small restaurant chain in the Lehigh Valley, and worked in the financial services industry.

Pat and Kris Toomey live in Zionsville with their three children Bridget, Patrick, and Duncan.



Robert Urban, PhD

Head of Corporate Innovation Center (Boston), Johnson and Johnson

In 2012 Robert was recruited to lead Johnson & Johnson's Boston Innovation Center. The investment teams at the Johnson & Johnson Innovation Centers work closely with entrepreneurs to advance products and technology up to proof-of-concept across the pharmaceuticals, medical device & diagnostic and consumer sectors. The Innovation Centers focus on people and programs that have the potential to not just advance healthcare, but to transform it. Located in Boston, Menlo Park, London and Shanghai, the J&J Innovation Centers seek to simplify and expedite the transformation of discoveries into healthcare products that improve lives across the world. Prior to J&J, Robert was the founding Executive Director of MIT's Institute for Integrative Cancer Research. Robert has held a variety of start-up, R&D leadership and advisory roles in the biopharmaceutical industry. Robert received his Bachelor of Arts degree in Microbiology and his PhD in Microbiology and Immunology from the University of Texas system and was an Irvington Fellow in structural immunology at Harvard University.



Dongmei Wang, PhD

Senior Vice President and General Manager, CMC Services Division, Frontage Laboratories Inc.

With nearly 20 years of pharmaceutical development experience, Dr. Wang's CMC operational oversight spans organic synthesis, formulation development, GMP analytical testing, and GMP manufacturing of clinical trial materials. Prior to joining Frontage in February 2007, Dr. Wang served as the director of analytical/QC at NovaDel Pharma Inc., where she led teams in providing support for NDA product development, clinical supplies manufacturing, CMC sections of regulatory filings, and technology transfer to commercial manufacturing sites. Prior to NovaDel, Dr. Wang headed pharmaceutical analysis and control group at Therics Inc. in product development for 510(k) and IND filings. Earlier in her career, Dr. Wang was a lecturer at the Graduate University of Chinese Academy of Science.

Dr. Wang earned a doctor of philosophy degree in chemistry with honors from Iowa State University followed by postdoctoral research at the University of Chicago. She received a master's degree in chemical engineering from Chinese Academy of Science and a bachelor's degree in chemistry from Peking University in China.



Lichun Wang, MS

Vice-President, Kelun Pharmaceutical Research Institute

Lichun Wang is Vice-President of Kelun Pharmaceutical Research Institute of Kelun Pharmaceutical, a pharmaceutical company headquartered in Chengdu, Sichuan and listed at Shenzhen Stock Exchange (SZ002422). In this capacity, Lichun Wang has applied for over 63 patents (45 invention patents), in which 34

patents were granted (27 invention patents). As a project leader and the main researcher, Lichun Wang was responsible for two projects named Kelun Incubator of new drug research and the innovation of Fat Emulsion Injections, both of which were national R&D projects. In addition, the project of bock greenbrier rhizome soft capsule gets the third prize of Sichuan Science and Technology Progress Award. He has completed 10 NDA applications and 4 IND applications.

Lichun Wang also serves as the deputy director of the local large volume injection Engineering Technical Research Center, the deputy director of the local large volume injection State Local United Engineering Laboratory, the office manager of State Identifying Enterprise Technology Center. He enjoys the special government allowances of Chengdu city and is the member of Innovator Talent Team in Sichuan province.

Previously, Lichun Wang worked as Analysis Director & QA in Sichuan Natural Pharmacy Institute, Sanlejiang Pharmaceutical and as Office Manager/Director Assistant in Southwest TCM Research Institute, China Sanyou Group.



Marinda Li Wu, PhD

2013 President, American Chemical Society (ACS)

Dr. Marinda Li Wu received a BS cum laude with Distinction in Chemistry from The Ohio State University in 1971 and a PhD in Inorganic Chemistry from the University of Illinois in 1976. With over thirty years of experience working in the chemical industry, she enjoyed many years working for Dow Chemical R&D as well as Dow Plastics Marketing forging partnerships between industry, education, government and communities. Dr. Wu also has entrepreneurial experience with various small chemical companies and startups including

"Science is Fun!" which she founded to engage young students in the excitement of science and enhance public awareness of the importance of supporting and improving science education.

As an ACS member for over forty years, Dr. Wu has served in many leadership roles at both the local and national levels for the American Chemical Society. Dr. Wu was elected to the ACS Board of Directors in 2006 and served as Director-at-Large until 2011. In 2011, she was elected to the Presidential succession of the American Chemical Society. As ACS President-Elect for 2012, she was invited to give plenary lectures worldwide and was made an honorary member of both the Romanian Chemical Society and the Polish Chemical Society. She traveled the world visiting chemistry communities as ACS President in 2013 and Immediate Past President in 2014.

Dr. Wu serves on the University of Illinois Chemistry Alumni Advisory Board, the International Advisory Board for the 45th IUPAC World Chemistry Congress 2015, and the Board of Directors for the Chinese-American Chemical Society. She holds 7 US Patents and has published a polymer textbook chapter and numerous articles in a variety of journals and magazines over the years.

Dr. Wu is co-editor of three ACS Symposium Books based on her ACS presidential symposia to be published in 2014 and 2015 and continues to share her message of "Partners for Progress and Prosperity" with science and technology communities worldwide.



Faming Zhang, PhD, MBA

Founder & CEO, Waterstone Pharmaceuticals, Inc.

Faming Zhang is the founder and CEO of Waterstone Pharmaceuticals, Inc. He also served as President of Crown Bioscience Inc., a leading preclinical biology CRO company. Prior to founding Waterstone and Crownbio, Dr. Zhang has spent 12 years at Eli Lilly & Co. While at Lilly, he had the responsibility as the global head of Drug Discovery and Development Statistics & Information Sciences. Dr. Zhang led Lilly's protein kinase/phosphatase structure-based drug design platform. He is the co-inventor of several patents in the area of kinase inhibitors and novel anti-obesity protein therapeutics. He also played a major role in the progression of cell cycle kinase inhibitors to the clinic. Dr. Zhang received his PhD in Biochemistry and Molecular Biology from Institute of Biophysics, Chinese Academy of Sciences and an MBA from Kelly Business School, Indiana University. He had 4 years of postdoctoral training from University of Texas Southwestern Medical Center in Dallas. He was also an Associate Professor of Chemistry and Biochemistry at Indiana University Bloomington. Dr. Zhang has authored more than 30 scientific publications.



De-Min Zhu, PhD

Chief Executive Officer, Cureport, Inc.

De-Min obtained his PhD degree in Physical Chemistry at Peking University, followed by 6 years of cross disciplinary postdoctoral research at NIH and Harvard Medical School in biochemistry, biophysics, immunology, and cancer research. He established the equation cited as Zhu-Golan Equation for the study of two dimensional interactions of proteins at cell-cell contact area. After postdoc research, De-Min joined Merck and then Pfizer where he developed his career and leadership in biopharmaceutical formulation/process for vaccines, biologics, and drug delivery. With strong support from a VC investment, De-Min founded Cureport, Inc. in 2012 in the United States, and has been serving the company as the President and CEO. He invented the proprietary nPort™ platform nanotechnology that brought a revolutionarily platform technology for liposome manufacturing from milligram to kilogram scales.

De-Min is one of the co-founders and loyal supporters of SAPA-GP. He served SAPA-GP at the Treasurer position from 2002 to 2009. He attended 11 of the 12 annual conferences of SAPA-GP.

Co-Organizers




Tianjin Binhai Anti-Cancer Drug
Development Industry Union



University of
Pennsylvania



Sponsors



武|汉|生|物|技|术|研|究|院
WUHAN INSTITUTE OF BIOTECHNOLOGY

Biolake
光谷生物城



科伦药业
KELUN PHARMACEUTICAL



Sundia

COVANCE
SOLUTIONS MADE REAL™



Bristol-Myers Squibb





Kelun, a large pharmaceutical company majoring in developing, manufacturing and distributing injection, branded generic drugs, NDDS, NCE projects and biotechnological drugs. The world's largest manufacturer of infusion products.

- In 2013, the sales of Kelun (Listed companies board) reached RMB 6.8 billion.
- The company's total assets ranked among the top 10 of China pharmaceutical companies.
- The Research Institute has over 287 R&D employees, including 23 PhD and 89 Master.



"Three engines" Strategy



Research System



Kelun Pharmaceutical
Research Institute



R&D Laboratory



Quality Analysis

Technical and project cooperation areas

- Innovative New Chemical Entities for oncology drugs
- New Drug Delivery System
- New biologic research (construction & screening, process, scale-up and quality control of monoclonal antibody cell line)
- Research & development for ANDA filling
- Patented and matured technologies in- and out-license or co-development

Invite for the experienced scientist & senior managers or consultants

- Experienced medicinal chemists (oncology)
- New drug screening and safety evaluation
- Formulation in DDS
- R&D and quality control for monoclonal antibody
- Clinical R&D and operation
- Regulatory affairs (international)
- Intellectual property Lawyer

Referrals will be appreciated

Website: www.kelun.com

E-Mail: wanglc@kelun.com

liwenjia@kelun.com

科伦药研 PHARMACEUTICAL RESEARCH

www.genscript.com



GenScript is a leading global CRO offering comprehensive services to support biological research and drug discovery. Specializing in customized reagent generation, antibody and protein engineering, and in vitro and in vivo pharmacology, we partner with customers by upholding core values of quality, speed, communication, and affordability. With headquarters in New Jersey, USA, GenScript has subsidiary companies in Europe, Japan and China.

CUSTOM REAGENT

-  Molecular Biology Services
-  Custom Peptide Services
-  Protein Expression Services
-  Custom Antibody Services
-  Cell Line Development Services

DISCOVERY BIOLOGY

-  Antibody Engineering
-  Bioprocess Development
-  Bio-Assay Service
-  Animal Model Service

CATALOG PRODUCT

-  Nucleic Acid Preparation & Analysis
-  Peptide & Biochemicals
-  PCR & Cloning
-  Cellular Analysis
-  Protein Expression, Isolation & Analysis
-  Catalog Antibodies



WE ARE SUNDIA!

Founded as a customer-focused and innovation-driven contract research organization (CRO) in 2004, Sundia is committed to provide high quality CRO services to pharmaceutical and biotech company clients worldwide, and to help our clients to bring drugs to the market more quickly and more safely.



*Your Partner for Drug
Discovery and Development*

- Top CRO in China
- Integrated R&D Services for Drug Discovery and Pharmaceutical Development
- Deloitte Technology Fast 500 Asia Pacific Award for 3 Consecutive Years



桑迪亚医药技术(上海)有限责任公司
Sundia MediTech Company, Ltd.

Tel: +86-21-51098642

www.sundia.com

SCIENTISTS HELPING SCIENTISTS.

At Covance, we help move science forward. Your science. As your research partner, we act as an extension of your team, providing the deep scientific expertise and unique perspectives that have helped deliver over a third of all the therapies on the market today. From custom assays to unique insights on helping reduce timelines and regulatory hurdles, Covance scientists are your scientists too. Come discover more about our experienced researchers and scientific experts.



CALL TO LEARN MORE

The Americas +1.888.COVANCE | Europe/Africa +800.2682.2682

Asia Pacific +800.6568.3000 | Or go to covance.com/scientist

COVANCE is an independent, publicly held company with headquarters in Princeton, New Jersey, USA.
COVANCE is the marketing name for Covance Inc. and its subsidiaries around the world. © Copyright 2014. Covance Inc.

COVANCE
SOLUTIONS MADE REAL™



Unleash your power
Drug Discovery on Target!

Solid Science | Innovative Technologies | Service Excellence
www.ptm-biolab.com



Pharmaron is a leading global pharmaceutical outsourcing company. Pharmaron (Beijing) located in Beijing economic technological development area (BDA) was founded in 2004 and has developed into a company with more than 2,000 employees and 770,000 ft² laboratories by the end of 2012.

With “enhancing the efficiency of drug development for the cooperative partner” for the purpose, Pharmaron provides high quality services across a number of disciplines including chemistry, biology, DMPK, pharmacology, toxicology and chemical development into an integrated R&D service.

Pharmaron’s key strength is the quality of its science. Pharmaron services are designed to our worldwide customers shorten the discovery and development time and lower the cost of drug R&D through cost-effective and efficient outsourcing solutions.

Sometimes

SIZE

really **does** matter

Probably the world's largest commercial collection of validated preclinical models for Oncology & Diabetes

- Over 1,000 well-characterised PDX (Patient-Derived Xenograft) *in vivo* models.
- Capacity to screen 100s of PDX models in parallel (Human Surrogate Clinical Trials).
- Over 330 validated, CDX (Cell line Derived Xenograft) *in vivo* models.
- Over 400 cell lines validated *in vitro* for screening.
- The world's largest collection of naturally diabetic NHPs.



www.crownbio.com



Kunming Biomed International (KBI), located in southwest China, is an AAALAC accredited contract research organization (CRO) providing preclinical research services specialized on non-human primates. The core competency of KBI stems from our expertise in developing and running specialized primate animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. Our developed clinical disease models are: CNS disease; metabolic diseases such as Type II diabetes, hyperlipidemia, hypertension and diabetic nephropathy; cardiovascular diseases like AMI and stroke; inflammatory / autoimmune diseases such as spontaneous rheumatoid arthritis (RA), CIA, spontaneous IBD, multiple sclerosis (EAE model), liver damage / fatty liver / liver fibrosis, etc. We also conduct adjacency studies in DMPK, histology/pathology, clinical chemistry, bioanalytics, safety pharmacology and non-GLP toxicology.

Tel & Fax: 86-871-5952827; Email: info@kbimed.com; www.kbimed.com



Address: NO.1 Boda Rd, Yuhua Area, Cheng-Gong New Town, Kunming, Yunnan, China, 650500

Accelerate Your Biotherapeutic Development

Rapidly identifying stable biotherapeutic formulations is critical to reducing development costs and determining a biotherapeutic's future success.

Malvern Instruments' expanding family of innovative Bioscience Solutions will accelerate the pace and productivity of your biotherapeutic development.

FORMULATION STABILITY



Zetasizer Nano ZSP
Protein size and charge, electrophoretic mobility, molecular weight, B_{22} , k_D



Viscotek GPC/SEC Systems
Absolute molecular weight, oligomeric purity, intrinsic viscosity, hydrodynamic size



Viscosizer 200
Automated viscosity (to 150 cP), size and concentration, < 10 μ L volume



Morphologi G3-ID
Automated particle size and shape, chemical identification of inherent, intrinsic, extrinsic particles



NanoSight NS300
Count, size, and visualize particles (10 – 2000nm) in real time. Ideal for monitoring protein aggregation.



Mastersizer 3000
Dry/Wet dispersion particle size



Jeffery W. Hall
Director of Business Development
443-878-1305 (w)/443-805-9389 (m)
Jeff.Hall@malvern.com

www.malvern.com

Bioscience Development Initiative. Malvern Instruments. 7221 Lee Deforest Drive, Suite 300. Columbia MD 21046

NEW YMC Separation Solutions for:

UHPLC, HPLC, Prep LC, SFC

YMC Meteoric Core-Shell HPLC Columns

C18, C8

- 2.7 μ m particle
- Superficially porous
- Faster run times
- Higher efficiencies
- Lower pressure

YMC Triart Hybrid Particle Columns

Five Different Phases

- HPLC and UHPLC
- C18, C8, Phenyl, PFP, HILIC
- pH 1-12 (C18, C8)
- Longer column life
- 1.9, 3, 5, 10, 15, 20, 50 μ m

YMC Chiral Polysaccharide Phases

YMC Chiral

- Amylose and Cellulose
- Familiar separations
- Robust and cost-effective
- Coated or immobilized
- 5, 10, 20 μ m

YMC
AMERICA, INC.

Email: info@ymcamerica.com
Phone: 610-266-8650
Website: www.ymcamerica.com
Online Store: store.ymcamerica.com

Browse the Website.
Buy Online.

PLUS: YMC's other proven solutions for reverse phase, normal phase, SEC, IEX. And SFC too!


Our projects
must be
completed
on time
and on budget.

We depend on Frontage.



For more information
on how we can help with
your next development
project, contact us at
sales@frontagelab.com
www.frontagelab.com
610-232-0100

**Drug
Development
Services:**
**DMPK
Bioanalytical
Clinical Research
CMC**



For over 50 years, Rockland Immunochemicals
has supported the Biomedical Research
Community with a full range of the highest
quality reagents and services.

Protect your experiments with
Rockland antibodies.

Purifications

Cell Culture Services

Secondary Antibodies

Conjugations




Custom Antibody Production

Blocking Buffers

Primary Antibodies

Molecular Biology Services

Blood Products



800.656.7625

info@rockland-inc.com

rockland-inc.com

Contact Information:

Alex Wang, Global Business Development
Cell: 86 -1803 6618 026 (CHN)
Email: wangdf@shhrp.com



Jiangsu Hengrui Medicine Co., Ltd.



Hengrui is a fully integrated pharmaceutical company based in China, with Rx drug sales of over \$1 billion (U.S.) in 2013. The company has been experiencing rapid growth in the past few years. It is recognized as the top innovative home-grown pharmaceutical company, with dozens of new molecular entities under clinical and pre-clinical development.

In China, Hengrui has a sales force of 4,500 dedicated professionals to reach out to a very broad base of healthcare providers across the country. They have attained the top market share in several segments, competing with both MNCs and domestic peers. Therapeutic focuses at Hengrui include oncology, surgical drugs, contrast media, metabolic diseases, cardiovascular, CNS, inflammation and hematology.

Hengrui delivers world-class product quality for the patients and takes pride in its manufacturing capability, which is up to the international cGMP standard. It got the first US ANDA approval in 2011, and has multiple ANDA submissions under US FDA and EMA review.


Hengrui is looking for partners to develop and commercialize its innovative products outside of China, as well as to in-license novel products to supplement its portfolio for the domestic market.

7 Kunlunshan Road, Lianyungang,, Jiangsu Province 222047, China

Tel: 800-828-3900 or 400-828-3900



Catalog Products Custom Synthesis Custom Manufacture GMP Compliance



17 years track record

250 dedicated employees

1000 bulk products for manufacture

20000 products listed (85% in stock) for R&D

We deliver the highest values to our clients, project by project

www.astatechinc.com

Keystone Business Park, 2525 Pearl Buck Road, Bristol, PA, USA, 215-785-3197



400+
Worldwide Clients

80+
Medicinal Chemistry Programs

20+
Preclinical Candidates Delivered Since 2008

10+
In IND Stage

5 Entered Phase I Clinical Trials

2 Entered Phase II Clinical Trials

1 Entered Phase III Clinical Trials (Breakthrough Designation)

**The Right Molecules.
Designed. Delivered.**

The International Discovery Service Unit (IDSU) is WuXi's solution to address our industry's drug discovery challenges through expertise in medicinal chemistry and program management. Visit us at www.wuxiapptec.com/idsu

IDSU

药明康德
WuXi AppTec



**It's Not Just A Submission,
It's Personal.**

Taking a drug or medical product to market is more than a series of steps in pursuit of approval. It's a proven approach; it's having the experience and expertise to meet the highest standards. It means doing the right thing, right. Because, at the end of the process, we're improving the lives of mothers, fathers, sisters, brothers, sons and daughters...and that is personal.

Providing end-to-end services in clinical development for Pharmaceutical, Biotech and Medical Device companies

K&L Consulting Services, Inc. has 400 FTE in U.S., China, Taiwan, Hong Kong, and South Korea, providing end to end clinical operation and biometrics services for clinical trial studies in U.S. and Asia.

K&L has been involved in 14 NDA submissions to FDA in past 3 years. This remarkable track record is based on many years of experience with the FDA, EMEA, CFDA and other regulatory agencies around the world.

K&L has been using a US-China centric model continues to provide clients with high quality clinical trial services in Asia, enrolled 20,000 patients through working with more than 300 investigators.

Our experienced staff, strong management, high standard of quality makes us a unique CRO service provider in the global pharmaceutical and biotechnology industry.

1300 Virginia Drive, Ste 408, Ft. Washington, PA

Contact: info@klserv.com/www.klserv.com

Next-Gen Sequencing Solutions for Optimizing Drug Discovery, Development and Diagnostics



Service

- * Genomics
- * Transcriptomics
- * Epigenomics
- * Proteomics
- * Genotyping
- * Bioinformatics



18 of the 20 Top Pharmas NOW Choose BGI!



www.bgitechsolutions.com

Shenzhen | Boston | Copenhagen | Hong Kong | Kobe

华大科技
BGI tech



When excellence is your goal, partner with **Ashland** for best-in-world pharmaceutical technologies

Ashland meets the needs of formulators by providing an unparalleled range of excipients and technologies, as well as longstanding polymer expertise and technical support from benchtop to commercialization for:

- Controlled-release formulations
- Drug solubilization
- Tablet binding
- Tablet film coating
- Tablet disintegration

Introducing Benece[™] DC HPMC

- Increased content uniformity
- Improved flow over existing controlled-release and directly compressible grades
- Lowered manufacturing costs
- Reduced development time

For more information, please contact your local Ashland Specialty Ingredients representative or visit us at ashland.com/pharmaceutical.

Visit Ashland at SAPA-GP Annual Conference 2014.



Alliance Pharma Your Trusted Partner

CORE CAPABILITIES

Alliance Pharma is a Contract Research Organization (CRO) **specializing in bioanalytical services** for both small and large molecules, and drug metabolism. Our extensive and diverse industrial experience includes:

- Analysis of drugs, agrochemicals and food ingredients
- Small molecule LC-MS/MS analysis
- Large molecule immunoassays
- Cell based assays
- Drug metabolism studies: drug-drug interactions (inhibition, induction), metabolic stability and protein binding

www.AlliancePharmaco.com



Cureport, Inc. is a VC-invested pharmaceutical company at 60 Prescott St. Worcester, MA. June 21, 2014 is Cureport's two-year anniversary. The company is committed to the development of nano technologies for medicine formulations. Cureport develops its core technologies in-house and contracts with CRO/CMO for research and GMP manufacturing. The company has established its proprietary nanoparticle technology platform, nPort™ that has brought a pharmaceutical revolutionary platform technology for liposome manufacturing from milligram to kilogram scales.

Cureport focuses on three business directions: (1) to produce generic nano medicines. Its CureDox, the generic liposomal drug Doxil, is at manufacture stage; (2) to develop proprietary nano formulations. The company has identified several promising novel formations for cancer treatment and is starting preclinical studies; (3) to collaborate with pharmaceutical partners. Currently, the company is conducting several collaborative projects.

Job and consulting opportunities at Cureport Inc:

- Senior Director, Manufacture
- Senior Scientist, formulation
- Senior Pharmaceutical Development Strategist / Consultant.
- Senior Marketing Consultant

hiring@cureportinc.com

Phone: 508-798-7788 Fax: 508-798-7787

www.cureportinc.com

About Biolake of Wuhan



Wuhan National Bio-industry Base, (i.e. Biolake), located in Wuhan East Lake Independent Innovation Demonstration Zone, is the second national industry base constructed with the principle of building a “100-billion industry” in the Optics Valley of China. With a total planning area of 30 square kilometers, focusing on 6 domains including bio-medicine, bio-agriculture, medical device, bio-manufacturing, medical service and bio-energy, 7 parks including Innovation Park, Bio-pharmaceutical Park, Bio-agriculture Park, Bio-manufacture Park, Medical Devices Park, Medical Health Park and Sino-Singapore Park are constructed, building a new town of bio-industry integrating R&D, incubation, production, logistics and living.



Biolake: your new opportunity, new start!



After 5 years of construction, Biolake always believes the development of industry should keep track with the world, the innovation should go along with the times. In 5 years, 6 platforms covering the fields of technical support, public service, enterprise incubation, information resource communication, finance and investment, and talent introduction are set up. 8 fortune global 500 companies, 11 listed companies, 258 national and international high-end entrepreneur groups are introduced, the leading indicators of the industry are increasing at an average annual rate of more than 40% growth, the target of “five 5” is achieved: 5 parks are fast developing, the constructed area reached 5,000,000 square kilometers, 518 enterprises are gathered, industry revenue exceeding 50 billion yuan, 5 world leading innovations successfully realized industrialization.



武汉生物|技术|研究院
WUHAN INSTITUTE OF BIOTECHNOLOGY

◎ 开放 ◎ 竞争 ◎ 联合 ◎ 共享
OPENING / COMPETITION / COLLABORATION / SHARING



WUHAN INSTITUTE OF BIOTECHNOLOGY

Locating at the Bio-Lake in the Donghu National Innovation Zone, Wuhan Institute of Biotechnology has been formed with the advantageous bio-tech resources provided by the Hubei Provincial Government. As the central research body and key organization, Wuhan Institute of Biotechnology is dedicated to the application, research and development of the biological technology, as well as providing technology services and the industrialization of research outcomes.

With a built-up area of 60,000 square meters, Wuhan Institute of Biotechnology consists of 6 centers — the Bio-tech Center, the Bio-Med Center, the Bio-Agriculture Center, the Bio-Environment Center, the Bio-Fuel Center as well as the Biomedical Engineering Center and 2 platforms—the Public Technology Service Platform and the Pilot Conversion Platform.

The most distinct feature of Wuhan Institute of Biotechnology is that it is constructed with the joint efforts from the Hubei Provincial Government, the local industry, national-famous universities and leading scholars and researchers. With the enterprise management and open operation, Wuhan Institute of Biotechnology enjoys all-dimension supporting services in the Bio-Lake, and is promoting new stock, finance and tax policies in the Donghu National Innovation Zone. As the major carrier of the pool resources, Wuhan Institute of Biotechnology shoulders national key scientific and research tasks.

Locating in the Bio-Lake and in the concept of open, competitive, joint and sharing, Wuhan Institute of Biotechnology is determined to grow as the top in Mid-China, outstanding nationwide and world-leading research institution.

政产学研交融协力的平台

- 湖北省委省政府聚集武汉大学、华中科技大学、华中农业大学、中科院武汉分院、凯迪控股等高校、科研院所、企业的优势资源

区域优势集成创新的基地

- 政府引导、产学研结合、市场化运行
- 理事会领导下的院长负责制
- 开放、竞争、联合、共享

生物产业做大做强的支撑

- 应用研究开发、专业服务和成果转化
- 武汉国家生物产业基地的技术支撑平台

人才聚集合力共赢的舞台

- 2009年启动建设，汇聚了8位两院院士在内的一大批国内外生物领域顶尖人才

